英文摘要 |
"Heart failure (HF) is the final common pathway of various cardiovascular diseases, leading to insufficient perfusion to vital organ systems. It is characterized by the heterogenous in etiology, complicated clinical course, and high frequency of recurrence. Corresponding therapeutic strategies include pharmacotherapy, percutaneous coronary intervention or surgery, mechanical assist devices, or even heart transplantation. The critical consideration is the comprehensiveness of disease management rather than piecemeal approach. Appropriate pharmacotherapy to HF patients can alleviate symptoms, reduce hospitalization, and improve survival. On the other hand, the multi-organ dysfunction and interrelated treatment modalities in HF patients urge the requirement of close monitor on pharmacokinetics and pharmacodynamics. This article addresses three pivotal issues about pharmacotherapy for patients with HF: resolving the etiology, consideration about comorbidities, and optimizing the treatment course." |